Product Description
BRY812 is a LIV-1 targeting ADC developed on BioRay's CysLink™ technology platform where highly stable conjugation is created through irreversible chemistry. By binding to LIV-1 on the surface of tumor cells, the ADC-target complex enters the tumor cell's lysosome through endocytosis, releasing small molecule toxins that selectively kill tumor cells. In pre-clinical pharmacological studies, BRY812 demonstrated significant antitumor activity in various tumor models. Compared to other ADCs targeting the same pathway, BRY812 has higher stability in circulation by eliminating payload exchange, delivering toxins more selectively to tumor tissue, which resulted in a superior safety profile in pre-clinical toxicology studies. (Sourced from: https://www.benzinga.com/pressreleases/23/05/n32545740/bioray-filed-ind-application-for-bry812-a-novel-antibody-drug-conjugate-targeting-liv-1)
Mechanisms of Action: SLC39A6 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioRay
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BRY812-ST-01 | P1 |
Not yet recruiting |
Pregnancy Outcomes |
2028-08-01 |
21% |
| CTR20232761 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |